REG - AstraZeneca PLC - Director Declaration <Origin Href="QuoteRef">AZN.L</Origin>

AstraZenecaAnnouncement

22/09/2016 11:00

RNS Number : 5617K
AstraZeneca PLC
22 September 2016
22 September 2016 11.00
New external board appointment
Listing Rule LR 9.6.14 R (2)
Ann Cairns, a Non-Executive Director of AstraZeneca PLC, is expected to join the Board of Directors of Intercontinental Exchange, Inc., a company listed on the New York Stock Exchange, effective from 2017.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com 
CONTACTS
Media Enquiries
Neil Burrows
UK/Global
+44 203 749 5637
Vanessa Rhodes
UK/Global
+44 203 749 5736
Karen Birmingham
UK/Global
+44 203 749 5634
Rob Skelding
UK/Global
+44 203 749 5821
Jacob Lund
Sweden
+46 8553260 20
Michele Meixell
US
+1 302 885 2677
Investor Relations


UK


Thomas Kudsk Larsen
+44 203 749 5712
Craig Marks
Finance, Fixed Income, M&A
+44 7881 615 764
Nick Stone
Respiratory & Autoimmunity
+44 203 749 5716
Henry Wheeler
Oncology
+44 203 749 5797
Christer Gruvris
Infection & Neuroscience
+44 203 749 5711
US


Lindsey Trickett
Cardiovascular & Metabolic Diseases
+1 240 543 7970
Mitchell Chan
Oncology
+1 240 477 3771
Toll-free

+1 866 381 7277
Adrian Kemp
Company Secretary
AstraZeneca PLC
-ENDS-

This information is provided by RNS
The company news service from the London Stock Exchange
  END
RDNKLLBLQKFXBBF